论文部分内容阅读
目的:探讨参麦注射液在急性白血病化疗中的应用价值,提高临床治疗水平。方法:选取我院收治的138例急性白血病患者,随机分为观察组(参麦注射液辅助治疗组)和对照组(常规化疗组)各69例,比较两组患者的治疗效果及不良反应情况。结果:观察组CR34例,PR27例,总有效率为88.4%;对照组CR18例,PR31例,总有效率为71.0%。两组患者比较差异显著(P<0.01)。观察组与对照组WBC治疗后均有所下降,但对照组较观察组下降明显(P<0.01);观察组PLT与Hb术前术后无明显改变,但较对照组有显著差异(P<0.01)。结论:参麦注射液辅助化疗治疗急性白血病可以提高治疗效果,改善治疗毒副反应症状和患者预后,值得临床推广应用。
Objective: To explore the value of Shenmai injection in the treatment of acute leukemia and improve the clinical treatment level. Methods: A total of 138 patients with acute leukemia admitted to our hospital were randomly divided into observation group (Shenmai injection adjuvant therapy group) and control group (conventional chemotherapy group), each with 69 cases. The therapeutic effect and adverse reactions of the two groups were compared . Results: The observation group CR34 cases, PR27 cases, the total effective rate was 88.4%; control group CR18 cases, PR31 cases, the total effective rate was 71.0%. The difference between the two groups was significant (P <0.01). Compared with the observation group, the observation group and the control group decreased after WBC treatment, but the control group showed a significant decrease (P <0.01). There was no significant difference between the observation group and the control group before and after WBC treatment (P < 0.01). Conclusion: Shenmai injection adjuvant chemotherapy in the treatment of acute leukemia can improve the therapeutic effect, improve the treatment of toxic and side effects and prognosis of patients, worthy of clinical application.